E
ETNB

Ergoteles’s 89bio ETNB Stock Holding History

Ergoteles’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-47,600
Closed -$153K – 1666
2022
Q2 		$153K Buy
+47,600
New +$144K ﹤0.01% 1410

Other funds holding ETNB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Ergoteles's ETNB Position: Q3 2022 in Review

Ergoteles sold out of 89bio (ETNB) in Q3 2022, closing a stake of 47,600 shares — an estimated $153K sold.

Ergoteles first reported a position in ETNB in Q2 2022 and held it in 1 quarter. The position peaked at $153K in Q2 2022. 86 funds tracked by Wall St. Rank hold ETNB as of Q3 2022.

  • Ergoteles reported no remaining 89bio position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 47,600 89bio shares in Q3 2022, an estimated $153K.
  • Ergoteles first reported a position in 89bio in Q2 2022 and held it in 1 quarter.
  • Ergoteles's 89bio position peaked at $153K in Q2 2022.
  • 86 funds tracked by Wall St. Rank held 89bio as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.